Mortality of Hemato-Oncologic Patients Admitted to a Pediatric Intensive Care Unit: A Single-Center Experience

Agnes Pechlaner1, Gabriele Kropshofer1, Roman Crazzolara1

  • 1Department of Paediatrics, Medical University of Innsbruck, Innsbruck, Austria.

Insights

Pediatric intensive care unit (PICU) admissions for children with hemato-oncologic disease are increasing. While emergency admissions show high mortality risks, overall outcomes appear better than previously reported.

Area of Science:

  • Pediatric critical care medicine
  • Pediatric hematology-oncology
  • Clinical outcomes research

Background:

  • Children with hemato-oncologic diseases face higher mortality in the pediatric intensive care unit (PICU).
  • Reasons for increased mortality in this vulnerable population remain underexplored.
  • Understanding trends and outcomes is crucial for improving care.

Purpose of the Study:

  • To assess outcomes and trends of hemato-oncologic patients admitted to the PICU.
  • To specifically analyze emergency admissions within this cohort.
  • To identify risk factors associated with mortality in PICU admissions.

Main Methods:

  • Retrospective analysis of 701 PICU admissions (2009-2019) in children with hemato-oncologic diagnoses.
  • Inclusion of 6-month and follow-up mortality data until December 2020.
  • Multivariable analysis to identify independent risk factors for PICU death.

Main Results:

  • A total of 701 PICU admissions were analyzed; 28.5% were emergency admissions.
  • Emergency admissions had a patient mortality of 18.0% and an admission mortality of 11.0%.
  • Severe neutropenia and invasive mechanical ventilation (IMV) were independent risk factors for PICU death (p=0.029 and p=0.002).
  • Total PICU admissions for these patients significantly increased from 44 (2009) to 125 (2019).

Conclusions:

  • Despite a high need for intensive organ support in emergency PICU admissions, mortality rates appear lower than previously reported.
  • The overall number of PICU admissions for hemato-oncologic patients has notably increased over the study period.
  • Further research into risk factors like severe neutropenia and IMV is warranted.
Abstract